CL2000002938A1 - Cristales del acido (e)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benciloxiimino]-4-fenilbutirico, composicion farmaceutica que los comprende y su uso en el tratamiento o prevencion de la diabetes mellitus, hiperlipemia, disminucion en la tolerancia a la glucosa, enfermedades inflamatorias, arteriosclerosis. - Google Patents
Cristales del acido (e)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benciloxiimino]-4-fenilbutirico, composicion farmaceutica que los comprende y su uso en el tratamiento o prevencion de la diabetes mellitus, hiperlipemia, disminucion en la tolerancia a la glucosa, enfermedades inflamatorias, arteriosclerosis.Info
- Publication number
- CL2000002938A1 CL2000002938A1 CL2000002938A CL2000002938A CL2000002938A1 CL 2000002938 A1 CL2000002938 A1 CL 2000002938A1 CL 2000002938 A CL2000002938 A CL 2000002938A CL 2000002938 A CL2000002938 A CL 2000002938A CL 2000002938 A1 CL2000002938 A1 CL 2000002938A1
- Authority
- CL
- Chile
- Prior art keywords
- crystals
- phenyl
- methyl
- oxazolylmethoxy
- benzyloxyimino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
CRISTALES DE ACIDO (E)-4-(5-METIL-2-FENIL-4- OXAZOLILMETOXI)BENZILOXIIMINO)-4-FENILBUTIRICO (CON LA CONDICION DE QUE LOS CRISTALES CUYO PUNTO DE FUSION FLUCTUA ENTRE 126 GRADOS C. Y 127 GRADOS C. QUEDEN EXCLUIDOS), LOS CUALES TIENEN UNA EXCELENTE ACCION CONTRA LA DIABETES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP30834699 | 1999-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2000002938A1 true CL2000002938A1 (es) | 2009-05-15 |
Family
ID=17979966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2000002938A CL2000002938A1 (es) | 1999-10-29 | 2000-10-26 | Cristales del acido (e)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benciloxiimino]-4-fenilbutirico, composicion farmaceutica que los comprende y su uso en el tratamiento o prevencion de la diabetes mellitus, hiperlipemia, disminucion en la tolerancia a la glucosa, enfermedades inflamatorias, arteriosclerosis. |
Country Status (19)
Country | Link |
---|---|
US (1) | US6777435B1 (es) |
EP (1) | EP1224178B1 (es) |
KR (1) | KR100433885B1 (es) |
CN (1) | CN1407975A (es) |
AR (1) | AR031078A1 (es) |
AT (1) | ATE243684T1 (es) |
AU (1) | AU7958100A (es) |
CA (1) | CA2388200A1 (es) |
CL (1) | CL2000002938A1 (es) |
CO (1) | CO5261530A1 (es) |
DE (1) | DE60003577T2 (es) |
HK (1) | HK1044536A1 (es) |
HU (1) | HUP0203884A3 (es) |
MY (1) | MY135840A (es) |
NO (1) | NO20022007L (es) |
PE (1) | PE20010761A1 (es) |
PL (1) | PL364171A1 (es) |
TW (1) | TW558554B (es) |
WO (1) | WO2001032637A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2403903A1 (en) * | 2000-03-28 | 2002-09-26 | Masatoshi Hazama | Angiogenesis inhibitors |
WO2002080936A1 (en) | 2001-04-04 | 2002-10-17 | Ortho Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
CA2443325C (en) * | 2001-04-04 | 2011-06-14 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
US7217697B2 (en) | 2001-05-30 | 2007-05-15 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor |
TWI327462B (en) * | 2002-01-18 | 2010-07-21 | Sumitomo Chemical Co | Condensed heterocyclic sulfonyl urea compound, a herbicide containing the same, and a method for weed control using the same |
CA2489145A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | Insulin-sensitizing agent |
US9132135B2 (en) * | 2004-09-24 | 2015-09-15 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
AU2005289808B2 (en) * | 2004-09-24 | 2011-11-03 | The Government Of The United States As Represented By The Secretary Of The Army, U.S. Army Medical Research Institute Of Chemical Defense | Method of treating organophosphorous poisoning |
US20090181887A1 (en) * | 2005-09-08 | 2009-07-16 | Gastrotech Pharma A/S | Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort |
TW201138843A (en) | 2009-12-18 | 2011-11-16 | Colgate Palmolive Co | Biguanide preservation of precipitated calcium carbonate |
US11191755B2 (en) | 2014-01-17 | 2021-12-07 | Cornell University | Compositions and methods for providing cardioprotective effects |
CA2937107C (en) * | 2014-01-17 | 2020-12-22 | Cornell University | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
KR102281228B1 (ko) | 2019-09-03 | 2021-07-22 | 신창수 | 과수나무의 가지지지용 파이프클램프 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL139470A0 (en) * | 1998-05-11 | 2001-11-25 | Takeda Chemical Industries Ltd | Oxyiminoalkanoic acid derivatives |
CA2389208A1 (en) * | 1999-10-29 | 2001-05-10 | Takeda Chemical Industries, Ltd. | Process for the preparation of oxyiminoalkanoic acid derivatives |
-
2000
- 2000-10-23 TW TW089122215A patent/TW558554B/zh active
- 2000-10-23 AR ARP000105570A patent/AR031078A1/es unknown
- 2000-10-24 MY MYPI20005001A patent/MY135840A/en unknown
- 2000-10-26 PE PE2000001148A patent/PE20010761A1/es not_active Application Discontinuation
- 2000-10-26 KR KR10-2001-7011003A patent/KR100433885B1/ko not_active IP Right Cessation
- 2000-10-26 AU AU79581/00A patent/AU7958100A/en not_active Abandoned
- 2000-10-26 HU HU0203884A patent/HUP0203884A3/hu unknown
- 2000-10-26 WO PCT/JP2000/007482 patent/WO2001032637A1/en active IP Right Grant
- 2000-10-26 CO CO00081698A patent/CO5261530A1/es not_active Application Discontinuation
- 2000-10-26 CL CL2000002938A patent/CL2000002938A1/es unknown
- 2000-10-26 PL PL00364171A patent/PL364171A1/xx not_active Application Discontinuation
- 2000-10-26 US US10/111,479 patent/US6777435B1/en not_active Expired - Fee Related
- 2000-10-26 CN CN00816789A patent/CN1407975A/zh active Pending
- 2000-10-26 DE DE60003577T patent/DE60003577T2/de not_active Expired - Fee Related
- 2000-10-26 CA CA002388200A patent/CA2388200A1/en not_active Abandoned
- 2000-10-26 EP EP00970081A patent/EP1224178B1/en not_active Expired - Lifetime
- 2000-10-26 AT AT00970081T patent/ATE243684T1/de not_active IP Right Cessation
-
2002
- 2002-04-26 NO NO20022007A patent/NO20022007L/no not_active Application Discontinuation
- 2002-08-21 HK HK02106108A patent/HK1044536A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MY135840A (en) | 2008-07-31 |
CO5261530A1 (es) | 2003-03-31 |
DE60003577T2 (de) | 2004-04-29 |
PE20010761A1 (es) | 2001-08-01 |
WO2001032637A1 (en) | 2001-05-10 |
HUP0203884A2 (hu) | 2003-03-28 |
NO20022007L (no) | 2002-06-24 |
AU7958100A (en) | 2001-05-14 |
KR20010102429A (ko) | 2001-11-15 |
AR031078A1 (es) | 2003-09-10 |
TW558554B (en) | 2003-10-21 |
ATE243684T1 (de) | 2003-07-15 |
EP1224178B1 (en) | 2003-06-25 |
CN1407975A (zh) | 2003-04-02 |
CA2388200A1 (en) | 2001-05-21 |
PL364171A1 (en) | 2004-12-13 |
KR100433885B1 (ko) | 2004-06-04 |
HUP0203884A3 (en) | 2005-01-28 |
DE60003577D1 (de) | 2003-07-31 |
NO20022007D0 (no) | 2002-04-26 |
EP1224178A1 (en) | 2002-07-24 |
HK1044536A1 (en) | 2002-10-25 |
US6777435B1 (en) | 2004-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2000002938A1 (es) | Cristales del acido (e)-4-[4-(5-metil-2-fenil-4-oxazolilmetoxi)benciloxiimino]-4-fenilbutirico, composicion farmaceutica que los comprende y su uso en el tratamiento o prevencion de la diabetes mellitus, hiperlipemia, disminucion en la tolerancia a la glucosa, enfermedades inflamatorias, arteriosclerosis. | |
MY145590A (en) | Phenylacetamides and their use as glucokinase modulators | |
BR0008379A (pt) | Epotilonas modificadas em c-21 | |
MXPA05007470A (es) | Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2. | |
ATE286715T1 (de) | Gastrointestinale an der mucosa haftende pharmazeutische zusammensetzung | |
NO20053537L (no) | Preparater og fremgangsmater for forebyggelse og kontroll av insulinindusert hypoglycemi. | |
AR016798A1 (es) | Uso de una cepa de lactobacillus para la elaboracion de un medicamento | |
CL2004000551A1 (es) | Compuestos derivados de triazol sustituidos con biarilo, sus sales, bloqueadores del canal de sodio; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento o prevencion del dolor. | |
DK1372650T3 (da) | Kombinationer indeholdende et antidiarrémiddel og en epothilon eller et epothilonderivat | |
DK0703786T3 (da) | Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS | |
BR0015992A (pt) | Compostos, utilização dos mesmos, e, associações terapêuticas | |
AR046210A1 (es) | Preparacion solida | |
PT92647A (pt) | Processo para a preparacao de 5-cloro-2-< { (3,4-dimetoxi-2-piridinil)-metil}-sulfinil>-1h-benzimidazol e de composicoes farmaceuticas que o contem | |
NO960775D0 (no) | Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner | |
AR028502A1 (es) | Tratamiento de condiciones inflamatorias alérgicas | |
NO20040702L (no) | Kombinerte preparater som inneholder 1,4-benzotiepin-1,1-dioksidderivater og andre aktive substanser og anvendelsen derav | |
BR0206960A (pt) | Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose | |
DE60312494D1 (de) | Optisch aktives pyridinderivat und medikament, das dieses enthält | |
BR9707083A (pt) | Formas sólidas de administração com liberação instantánea e processos para a sua produção | |
RS50136B (sr) | Derivati tiazolidindiona i njihova upotreba kao antidijabetika | |
NO20032597L (no) | Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma | |
PE20030277A1 (es) | Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa | |
WO2005036109A3 (en) | Integrating ultraviolet exposure detection devices | |
ECSP034469A (es) | Compuesto farmaceutico novedoso | |
DE68906245D1 (de) | Therapeutisches mittel gegen aids. |